Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Novo Nordisk A/S — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.33, while Novo Nordisk A/S trades at $46.24 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | NVO | |
|---|---|---|
52-Week High | $75.17 | $63.98 |
52-Week Low | $72.15 | $35.29 |
Market Cap | — | $207.85B |
Sector | — | Health |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.36, up 0.29% today, amid a bearish technical outlook with moving averages signaling sell pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, 2026-08-05), while broader bond ETF inflows reached nearly $300 billion in H1 2026 (Zacks Investment Research, 2026-08-06).
The outlook remains cautious due to technical weakness and interest rate sensitivity, but BND offers income stability through dividends. Risks include Treasury yield volatility and inflation data impacts, yet it serves as a core fixed-income holding for diversification amid market uncertainty.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
